Related references
Note: Only part of the references are listed.Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease
Ryota Shibaki et al.
MEDICAL ONCOLOGY (2019)
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
Osamu Kanai et al.
THORACIC CANCER (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
Karthik Suresh et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characteristics, incidence, and risk factors of immune checkpoint inhibitor related pneumonitis in patients with non-small cell lung cancer
Jun Yeun Cho et al.
LUNG CANCER (2018)
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia
Daichi Fujimoto et al.
LUNG CANCER (2017)
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
Hirotsugu Kenmotsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer
Yasunori Enomoto et al.
LUNG CANCER (2016)
Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Daichi Fujimoto et al.
PLOS ONE (2016)
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer
Mizuki Nishino et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia
Takahiro Omori et al.
ANNALS OF THORACIC SURGERY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Clostridium difficile Infection
Daniel A. Leffler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Consensus statement for the diagnosis and treatment of drug-induced lung injuries
Keishi Kubo et al.
RESPIRATORY INVESTIGATION (2013)
The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK
Ivan Le Jeune et al.
RESPIRATORY MEDICINE (2007)
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib
M Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Clinical advances in the diagnosis and therapy of the interstitial lung diseases
TE King
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Severe acute interstitial pneumonia and gefitinib
A Inoue et al.
LANCET (2003)
Lung cancer and cryptogenic fibrosing alveolitis - A population-based cohort study
R Hubbard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
